Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL720615

CC(C)Oc1cc(OCCc2ccccc2)cc(-c2nc3cccnc3[nH]2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 8/20 0.45
PTGES O14684 2/20 0.40
ALOX5 P09917 2/20 0.40
PPARG P37231 2/20 0.40
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
CBFB Q13951 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NSD2 O96028 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711181 0.92 GCK (0.45) GCKPTGESALOX5PPARGPDE4A
Trifluoroacetic Acid SCHEMBL713011 0.91 GCK (0.44) GCKCBFB
Trifluoroacetic Acid SCHEMBL712661 0.89 CHEK2 (0.41) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL711559 0.87 GCK (0.46) GCKPTGESALOX5PPARGCBFB
Trifluoroacetic Acid SCHEMBL709569 0.87 DHODH (0.43) GCK
Trifluoroacetic Acid SCHEMBL709188 0.86 GCK (0.39) GCKPDE4BCBFB
Trifluoroacetic Acid SCHEMBL713667 0.85 GCK (0.47) GCKSMN1; SMN2KDM4ENSD2ALDH1A1
Trifluoroacetic Acid SCHEMBL709930 0.85 GCK (0.48) GCKCBFBSMN1; SMN2TP53MAPT
Trifluoroacetic Acid SCHEMBL710679 0.84 ACHE (0.44)
Trifluoroacetic Acid SCHEMBL718789 0.84 PDE4A (0.35) PTGESALOX5PPARGPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GCK 1/4885PTGES 2068/4885ALOX5 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.